Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IDEAYA Biosciences, Inc.IDYA · Entity 4069 | SVP, General Counsel | January 30, 2026 | February 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IDEAYA Biosciences, Inc.
Report date January 30, 2026 · Filed February 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,080 |
Ending reported balance
After 2025-11-28 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-05-30 · Grant · Acquired 1,039 · Balance 1,039 F1: The shares were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Row 2 · 2025-11-28 · Grant · Acquired 1,041 · Balance 2,080 F1: The shares were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.19 · Expires 2036-01-30 | Direct | 130,000 |
Reported balance
After 2026-01-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-01-30 · Grant · Acquired 130,000 · Balance 130,000 F2: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F2: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
GW PHARMACEUTICALS PLC
Report date May 05, 2021 · Filed May 07, 2021
Section 16 reporting ended · disclosed 2021-05-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 1
1 source rowRow 1 · 2021-05-05 · Disposition to issuer · Disposed 61,848 · Balance 0 F1: On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement") (continued in footnote 2). F2: At the effective time of the Scheme of Arrangement, Scheme Shareholders (as defined in the Scheme of Arrangement) became entitled to receive for each Scheme Share (as defined in the Scheme of Arrangement) held by them an amount equal to $16.66 2/3 in cash plus 0.010030 ordinary shares, nominal value $0.0001 per share, of Jazz ("Jazz ordinary shares"). The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $8.38 · Expires 2027-08-10 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-05-05 · Disposition to issuer · Disposed 82,956 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $9.61 · Expires 2028-02-26 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-05-05 · Disposition to issuer · Disposed 63,252 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $14.33 · Expires 2029-03-01 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-05-05 · Disposition to issuer · Disposed 46,644 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-05-05 · Disposition to issuer · Disposed 9,180 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5: These stock options were granted with automatic vesting on exercisable date. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-05-05 · Disposition to issuer · Disposed 9,612 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5: These stock options were granted with automatic vesting on exercisable date. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-05-05 · Disposition to issuer · Disposed 88,524 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5: These stock options were granted with automatic vesting on exercisable date. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-05-05 · Disposition to issuer · Disposed 13,272 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5: These stock options were granted with automatic vesting on exercisable date. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2021-05-05 · Disposition to issuer · Disposed 149,856 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5: These stock options were granted with automatic vesting on exercisable date. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2021-05-05 · Disposition to issuer · Disposed 89,952 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5: These stock options were granted with automatic vesting on exercisable date. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2021-05-05 · Disposition to issuer · Disposed 45,360 · Balance 0 F4: Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023. F5: These stock options were granted with automatic vesting on exercisable date. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2021-05-05 · Disposition to issuer · Disposed 72,528 · Balance 0 F4: Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023. F5: These stock options were granted with automatic vesting on exercisable date. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement") (continued in footnote 2).
F2: At the effective time of the Scheme of Arrangement, Scheme Shareholders (as defined in the Scheme of Arrangement) became entitled to receive for each Scheme Share (as defined in the Scheme of Arrangement) held by them an amount equal to $16.66 2/3 in cash plus 0.010030 ordinary shares, nominal value $0.0001 per share, of Jazz ("Jazz ordinary shares"). The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021.
F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration.
F4: Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023.
F5: These stock options were granted with automatic vesting on exercisable date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 30, 2026 Filed Feb 3, 2026 00:57 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | GrantStock Option (right to buy) · Derivative | 130,000 | $0.00 Strike: $32.19 | $0.00 |
DisclosureSEC source: 0001610717-26-000033 · form4.xml · derivative · entry 3 Snyder Douglas B. · CIK 0001754125 · SVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2036-01-30 F2 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| November 28, 2025 Filed Feb 3, 2026 00:57 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | GrantCommon Stock | 1,041 | $16.91 | $17,599.67 |
DisclosureSEC source: 0001610717-26-000033 · form4.xml · nonDerivative · entry 2 Snyder Douglas B. · CIK 0001754125 · SVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,080 F1 · kind: The shares were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| May 30, 2025 Filed Feb 3, 2026 00:57 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | GrantCommon Stock | 1,039 | $16.91 | $17,565.85 |
DisclosureSEC source: 0001610717-26-000033 · form4.xml · nonDerivative · entry 1 Snyder Douglas B. · CIK 0001754125 · SVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,039 F1 · kind: The shares were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 27, 2025 Filed Feb 28, 2025 23:00 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | GrantStock Option (right to buy) · Derivative | 33,000 | $0.00 Strike: $20.24 | $0.00 |
DisclosureSEC source: 0001610717-25-000039 · form4.xml · derivative · entry 1 Snyder Douglas B. · CIK 0001754125 · SVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,000 Underlying: Common Stock · 33,000 shares Expires 2035-02-26 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| September 26, 2024 Filed Sep 27, 2024 20:25 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | GrantStock Option (Right to Buy) · Derivative | 140,000 | $0.00 Strike: $30.50 | $0.00 |
DisclosureSEC source: 0001610717-24-000497 · form4.xml · derivative · entry 1 Snyder Douglas B. · CIK 0001754125 · SVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2034-09-25 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from September 18, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| May 05, 2021 Filed May 7, 2021 16:15 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Disposition to issuerShare Options · Derivative | 72,528 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000899243-21-018666 · doc4.xml · derivative · entry 12 Snyder Douglas B. · CIK 0001754125 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 72,528 shares Expires not disclosed F4 · price: Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023. F4 · derivative.exercise_date: Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023. F5 · derivative.expiration_date: These stock options were granted with automatic vesting on exercisable date. Read SEC document |
| May 05, 2021 Filed May 7, 2021 16:15 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Disposition to issuerShare Options · Derivative | 45,360 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000899243-21-018666 · doc4.xml · derivative · entry 11 Snyder Douglas B. · CIK 0001754125 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 45,360 shares Expires not disclosed F4 · price: Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023. F4 · derivative.exercise_date: Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023. F5 · derivative.expiration_date: These stock options were granted with automatic vesting on exercisable date. Read SEC document |
| May 05, 2021 Filed May 7, 2021 16:15 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Disposition to issuerShare Options · Derivative | 89,952 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000899243-21-018666 · doc4.xml · derivative · entry 10 Snyder Douglas B. · CIK 0001754125 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 89,952 shares Expires not disclosed F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5 · derivative.expiration_date: These stock options were granted with automatic vesting on exercisable date. Read SEC document |
| May 05, 2021 Filed May 7, 2021 16:15 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Disposition to issuerShare Options · Derivative | 149,856 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000899243-21-018666 · doc4.xml · derivative · entry 9 Snyder Douglas B. · CIK 0001754125 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 149,856 shares Expires not disclosed F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5 · derivative.expiration_date: These stock options were granted with automatic vesting on exercisable date. Read SEC document |
| May 05, 2021 Filed May 7, 2021 16:15 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Disposition to issuerShare Options · Derivative | 13,272 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000899243-21-018666 · doc4.xml · derivative · entry 8 Snyder Douglas B. · CIK 0001754125 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 13,272 shares Expires not disclosed F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5 · derivative.expiration_date: These stock options were granted with automatic vesting on exercisable date. Read SEC document |
| May 05, 2021 Filed May 7, 2021 16:15 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Disposition to issuerShare Options · Derivative | 88,524 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000899243-21-018666 · doc4.xml · derivative · entry 7 Snyder Douglas B. · CIK 0001754125 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 88,524 shares Expires not disclosed F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5 · derivative.expiration_date: These stock options were granted with automatic vesting on exercisable date. Read SEC document |
| May 05, 2021 Filed May 7, 2021 16:15 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Disposition to issuerShare Options · Derivative | 9,612 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000899243-21-018666 · doc4.xml · derivative · entry 6 Snyder Douglas B. · CIK 0001754125 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 9,612 shares Expires not disclosed F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5 · derivative.expiration_date: These stock options were granted with automatic vesting on exercisable date. Read SEC document |
| May 05, 2021 Filed May 7, 2021 16:15 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Disposition to issuerShare Options · Derivative | 9,180 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000899243-21-018666 · doc4.xml · derivative · entry 5 Snyder Douglas B. · CIK 0001754125 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 9,180 shares Expires not disclosed F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5 · derivative.expiration_date: These stock options were granted with automatic vesting on exercisable date. Read SEC document |
| May 05, 2021 Filed May 7, 2021 16:15 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Disposition to issuerShare Options · Derivative | 46,644 | Not disclosed Strike: $14.33 | Not disclosed |
DisclosureSEC source: 0000899243-21-018666 · doc4.xml · derivative · entry 4 Snyder Douglas B. · CIK 0001754125 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 46,644 shares Expires 2029-03-01 F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. Read SEC document |
| May 05, 2021 Filed May 7, 2021 16:15 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Disposition to issuerShare Options · Derivative | 63,252 | Not disclosed Strike: $9.61 | Not disclosed |
DisclosureSEC source: 0000899243-21-018666 · doc4.xml · derivative · entry 3 Snyder Douglas B. · CIK 0001754125 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 63,252 shares Expires 2028-02-26 F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. Read SEC document |
| May 05, 2021 Filed May 7, 2021 16:15 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Disposition to issuerShare Options · Derivative | 82,956 | Not disclosed Strike: $8.38 | Not disclosed |
DisclosureSEC source: 0000899243-21-018666 · doc4.xml · derivative · entry 2 Snyder Douglas B. · CIK 0001754125 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 82,956 shares Expires 2027-08-10 F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. Read SEC document |
| May 05, 2021 Filed May 7, 2021 16:15 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Disposition to issuerOrdinary Shares | 61,848 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-018666 · doc4.xml · nonDerivative · entry 1 Snyder Douglas B. · CIK 0001754125 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement") (continued in footnote 2). F2 · price: At the effective time of the Scheme of Arrangement, Scheme Shareholders (as defined in the Scheme of Arrangement) became entitled to receive for each Scheme Share (as defined in the Scheme of Arrangement) held by them an amount equal to $16.66 2/3 in cash plus 0.010030 ordinary shares, nominal value $0.0001 per share, of Jazz ("Jazz ordinary shares"). The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021. Read SEC document |
| March 26, 2021 Filed Apr 8, 2021 20:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | SaleOrdinary Shares | 8,400 | $18.12 | $152,208.00 |
DisclosureSEC source: 0000899243-21-015430 · doc4.xml · nonDerivative · entry 1 Snyder Douglas B. · CIK 0001754125 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,848 F1 · shares: Represented by American Depositary Shares of the Issuer ("ADS"). Each ADS represents twelve ordinary shares of the Issuer. F2 · price: The price reported in Column 4 is a price per ordinary share converted from price per ADS. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 21:01 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | GrantShare Options · Derivative | 45,360 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-010018 · doc4.xml · derivative · entry 2 Snyder Douglas B. · CIK 0001754125 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,360 Underlying: Ordinary Shares · 45,360 shares Expires not disclosed F3 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. F6 · security: The share numbers underlying options granted on February 22, 2021 and reported on the reporting person's form 4 filed on February 24, 2021 were amended as of March 2, 2021 and as reported in this form 4. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.41 U.S. Dollars as of February 22, 2021. F4 · derivative.exercise_date: These share options will vest in four equal annual installments beginning on February 22, 2022 and be automatically exercised upon vesting. F5 · derivative.exercise_date: Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc. F4 · derivative.expiration_date: These share options will vest in four equal annual installments beginning on February 22, 2022 and be automatically exercised upon vesting. F5 · derivative.expiration_date: Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 21:01 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | GrantShare Options · Derivative | 72,258 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-010018 · doc4.xml · derivative · entry 1 Snyder Douglas B. · CIK 0001754125 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,258 Underlying: Ordinary Shares · 72,258 shares Expires not disclosed F1 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest and be automatically exercised on February 22, 2024 if certain performance conditions are satisfied. F6 · security: The share numbers underlying options granted on February 22, 2021 and reported on the reporting person's form 4 filed on February 24, 2021 were amended as of March 2, 2021 and as reported in this form 4. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.41 U.S. Dollars as of February 22, 2021. F1 · derivative.exercise_date: Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest and be automatically exercised on February 22, 2024 if certain performance conditions are satisfied. F5 · derivative.exercise_date: Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc. F1 · derivative.expiration_date: Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest and be automatically exercised on February 22, 2024 if certain performance conditions are satisfied. F5 · derivative.expiration_date: Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:42 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionShare Options · Derivative | 6,636 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-009225 · doc4.xml · derivative · entry 9 Snyder Douglas B. · CIK 0001754125 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,636 shares Expires 2021-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.39 U.S. Dollars as of March 1, 2021. F1 · kind: Exercise of share options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:42 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Tax withholdingOrdinary Shares | 3,408 | $17.85 | $60,832.80 |
DisclosureSEC source: 0000899243-21-009225 · doc4.xml · nonDerivative · entry 6 Snyder Douglas B. · CIK 0001754125 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,248 F3 · kind: Withhold to cover vested RSU style share options. F4 · shares: Represented by ADS. F5 · price: The price reported is price per ordinary share converted from price per ADS. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:42 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionOrdinary Shares | 6,636 | $0.00 | $9.29 |
DisclosureSEC source: 0000899243-21-009225 · doc4.xml · nonDerivative · entry 5 Snyder Douglas B. · CIK 0001754125 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,656 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of share options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F2 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.39 U.S. Dollars as of February 26, 2021. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 21:42 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionShare Options · Derivative | 9,612 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-009225 · doc4.xml · derivative · entry 8 Snyder Douglas B. · CIK 0001754125 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 9,612 shares Expires 2021-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.39 U.S. Dollars as of February 26, 2021. F1 · kind: Exercise of share options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 21:42 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionShare Options · Derivative | 128,172 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-009225 · doc4.xml · derivative · entry 7 Snyder Douglas B. · CIK 0001754125 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 128,172 shares Expires 2021-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.39 U.S. Dollars as of February 26, 2021. F1 · kind: Exercise of share options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 21:42 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Tax withholdingOrdinary Shares | 4,937 | $17.90 | $88,372.30 |
DisclosureSEC source: 0000899243-21-009225 · doc4.xml · nonDerivative · entry 4 Snyder Douglas B. · CIK 0001754125 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,020 F3 · kind: Withhold to cover vested RSU style share options. F4 · shares: Represented by ADS. F5 · price: The price reported is price per ordinary share converted from price per ADS. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 21:42 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionOrdinary Shares | 9,612 | $0.00 | $13.46 |
DisclosureSEC source: 0000899243-21-009225 · doc4.xml · nonDerivative · entry 3 Snyder Douglas B. · CIK 0001754125 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,957 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of share options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F2 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.39 U.S. Dollars as of February 26, 2021. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 21:42 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Tax withholdingOrdinary Shares | 65,827 | $17.90 | $1,178,303.30 |
DisclosureSEC source: 0000899243-21-009225 · doc4.xml · nonDerivative · entry 2 Snyder Douglas B. · CIK 0001754125 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,345 F3 · kind: Withhold to cover vested RSU style share options. F4 · shares: Represented by ADS. F5 · price: The price reported is price per ordinary share converted from price per ADS. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 21:42 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionOrdinary Shares | 128,172 | $0.00 | $179.44 |
DisclosureSEC source: 0000899243-21-009225 · doc4.xml · nonDerivative · entry 1 Snyder Douglas B. · CIK 0001754125 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,172 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of share options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F2 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.39 U.S. Dollars as of February 26, 2021. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 18:51 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | GrantShare Options · Derivative | 72,528 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-008097 · doc4.xml · derivative · entry 2 Snyder Douglas B. · CIK 0001754125 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,528 Underlying: Ordinary Shares · 72,528 shares Expires not disclosed F3 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.41 U.S. Dollars as of February 22, 2021. F4 · derivative.exercise_date: These share options will vest in four equal annual installments beginning on February 22, 2022 and be automatically exercised upon vesting. F5 · derivative.exercise_date: Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc. F4 · derivative.expiration_date: These share options will vest in four equal annual installments beginning on February 22, 2022 and be automatically exercised upon vesting. F5 · derivative.expiration_date: Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 18:51 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | GrantShare Options · Derivative | 45,324 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-008097 · doc4.xml · derivative · entry 1 Snyder Douglas B. · CIK 0001754125 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,324 Underlying: Ordinary Shares · 45,324 shares Expires not disclosed F1 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest and be automatically exercised on February 22, 2024 if certain performance conditions are satisfied. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.41 U.S. Dollars as of February 22, 2021. F1 · derivative.exercise_date: Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest and be automatically exercised on February 22, 2024 if certain performance conditions are satisfied. F5 · derivative.exercise_date: Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc. F1 · derivative.expiration_date: Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest and be automatically exercised on February 22, 2024 if certain performance conditions are satisfied. F5 · derivative.expiration_date: Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc. Read SEC document |
| December 07, 2020 Filed Dec 9, 2020 20:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | SaleOrdinary Shares | 2,400 | $11.30 | $27,120.00 |
DisclosureSEC source: 0000899243-20-033216 · doc4.xml · nonDerivative · entry 6 Snyder Douglas B. · CIK 0001754125 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 6, 2020. F2 · shares: Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F8 · price: Converted from price per ADS. The price reported in Column 4 is a weighted average price per ordinary share ($135.6500 per ADS). These shares were sold in multiple transactions at prices ranging from $135.65 per ADS (or $11.30 per ordinary share) to $135.65 per ADS (or $11.30 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 07, 2020 Filed Dec 9, 2020 20:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | SaleOrdinary Shares | 1,200 | $11.19 | $13,428.00 |
DisclosureSEC source: 0000899243-20-033216 · doc4.xml · nonDerivative · entry 5 Snyder Douglas B. · CIK 0001754125 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,400 F1 · kind: The sale reported was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 6, 2020. F2 · shares: Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F7 · price: Converted from price per ADS. The price reported in Column 4 is a weighted average price per ordinary share ($134.3200 per ADS). These shares were sold in multiple transactions at prices ranging from $134.32 per ADS (or $11.19 per ordinary share) to $134.32 per ADS (or $11.19 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 07, 2020 Filed Dec 9, 2020 20:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | SaleOrdinary Shares | 5,076 | $11.11 | $56,394.36 |
DisclosureSEC source: 0000899243-20-033216 · doc4.xml · nonDerivative · entry 4 Snyder Douglas B. · CIK 0001754125 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,600 F1 · kind: The sale reported was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 6, 2020. F2 · shares: Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F6 · price: Converted from price per ADS. The price reported in Column 4 is a weighted average price per ordinary share ($133.2948 per ADS). These shares were sold in multiple transactions at prices ranging from $132.90 per ADS (or $11.08 per ordinary share) to $133.64 per ADS (or $11.14 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 07, 2020 Filed Dec 9, 2020 20:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | SaleOrdinary Shares | 3,984 | $11.02 | $43,903.68 |
DisclosureSEC source: 0000899243-20-033216 · doc4.xml · nonDerivative · entry 3 Snyder Douglas B. · CIK 0001754125 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,676 F1 · kind: The sale reported was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 6, 2020. F2 · shares: Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F5 · price: Converted from price per ADS. The price reported in Column 4 is a weighted average price per ordinary share ($132.2066 per ADS). These shares were sold in multiple transactions at prices ranging from $131.87 per ADS (or $10.99 per ordinary share) to $132.30 per ADS (or $11.03 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 07, 2020 Filed Dec 9, 2020 20:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | SaleOrdinary Shares | 9,444 | $10.95 | $103,411.80 |
DisclosureSEC source: 0000899243-20-033216 · doc4.xml · nonDerivative · entry 2 Snyder Douglas B. · CIK 0001754125 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,660 F1 · kind: The sale reported was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 6, 2020. F2 · shares: Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F4 · price: Converted from price per ADS. The price reported in Column 4 is a weighted average price per ordinary share ($131.3749 per ADS). These shares were sold in multiple transactions at prices ranging from $130.83 per ADS (or $10.90 per ordinary share) to $131.81 per ADS (or $10.98 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 07, 2020 Filed Dec 9, 2020 20:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | SaleOrdinary Shares | 4,800 | $10.84 | $52,032.00 |
DisclosureSEC source: 0000899243-20-033216 · doc4.xml · nonDerivative · entry 1 Snyder Douglas B. · CIK 0001754125 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,104 F1 · kind: The sale reported was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 6, 2020. F2 · shares: Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F3 · price: Converted from price per ADS. The price reported in Column 4 is a weighted average price per ordinary share ($130.0325 per ADS). These shares were sold in multiple transactions at prices ranging from $129.69 per ADS (or $10.81 per ordinary share) to $130.50 per ADS (or $10.88 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 16:40 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | SaleOrdinary Shares | 14,400 | $8.13 | $117,072.00 |
DisclosureSEC source: 0000899243-20-026863 · doc4.xml · nonDerivative · entry 1 Snyder Douglas B. · CIK 0001754125 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,904 F1 · kind: The sale reported was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 13, 2020. F2 · shares: Represented by American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F3 · price: The price reported is price per ordinary share converted from price per ADS. Read SEC document |
| August 11, 2020 Filed Aug 12, 2020 20:06 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | SaleOrdinary Shares | 24,000 | $9.40 | $225,600.00 |
DisclosureSEC source: 0000899243-20-022190 · doc4.xml · nonDerivative · entry 5 Snyder Douglas B. · CIK 0001754125 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,304 F6 · kind: The sale reported was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2020. F4 · shares: Represented by ADS. F5 · price: The price reported is price per ordinary share converted from price per ADS. Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 20:06 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionStock Options · Derivative | 9,180 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-022190 · doc4.xml · derivative · entry 7 Snyder Douglas B. · CIK 0001754125 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 9,180 shares Expires 2020-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.31 U.S. Dollars as of August 10, 2020. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 20:06 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionStock Options · Derivative | 122,364 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-022190 · doc4.xml · derivative · entry 6 Snyder Douglas B. · CIK 0001754125 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 122,364 shares Expires 2020-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.31 U.S. Dollars as of August 10, 2020. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 20:06 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Tax withholdingOrdinary Shares | 9,180 | $9.11 | $83,629.80 |
DisclosureSEC source: 0000899243-20-022190 · doc4.xml · nonDerivative · entry 4 Snyder Douglas B. · CIK 0001754125 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,304 F3 · kind: Withhold to cover vested RSU style share options. F5 · price: The price reported is price per ordinary share converted from price per ADS. Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 20:06 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionOrdinary Shares | 9,180 | $0.00 | $11.93 |
DisclosureSEC source: 0000899243-20-022190 · doc4.xml · nonDerivative · entry 3 Snyder Douglas B. · CIK 0001754125 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,484 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F2 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.31 U.S. Dollars as of August 10, 2020. Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 20:06 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Tax withholdingOrdinary Shares | 57,060 | $9.11 | $519,816.60 |
DisclosureSEC source: 0000899243-20-022190 · doc4.xml · nonDerivative · entry 2 Snyder Douglas B. · CIK 0001754125 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,304 F3 · kind: Withhold to cover vested RSU style share options. F5 · price: The price reported is price per ordinary share converted from price per ADS. Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 20:06 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionOrdinary Shares | 122,364 | $0.00 | $159.07 |
DisclosureSEC source: 0000899243-20-022190 · doc4.xml · nonDerivative · entry 1 Snyder Douglas B. · CIK 0001754125 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,364 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F2 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.31 U.S. Dollars as of August 10, 2020. Read SEC document |
| July 06, 2020 Filed Jul 8, 2020 20:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | SaleOrdinary Shares | 9,804 | $10.50 | $102,942.00 |
DisclosureSEC source: 0000899243-20-018765 · doc4.xml · nonDerivative · entry 1 Snyder Douglas B. · CIK 0001754125 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2020. F2 · shares: Represented by American Depositary Shares of the Issuer ("ADS"). Each ADS represents twelve ordinary shares of the Issuer. F3 · price: The price reported is price per ordinary share converted from price per ADS. F4 · balance_after: Column 5 of Table I of the reporting person's Form 4 filed with the SEC on March 4, 2020 includes 57,492 ordinary shares underlying RSU style share options granted pursuant to the Issuer's Long-Term Incentive Plan, including (i) 19,908 ordinary shares vesting automatically in two equal installments on August 10, 2020 and 2021, (ii) 19,224 ordinary shares vesting automatically in two equal installments on February 26, 2021 and 2022, and (iii) 18,360 ordinary shares vesting automatically in three equal installments on March 1, 2021, 2022, and 2023. These ordinary shares have been excluded from Column 5 of this Form 4 and will be reported as each tranche is vested and automatically exercised. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 20:06 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | GrantShare Options · Derivative | 89,952 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-015701 · doc4.xml · derivative · entry 2 Snyder Douglas B. · CIK 0001754125 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,952 Underlying: Ordinary Shares · 89,952 shares Expires not disclosed F2 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. F3 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.26 U.S. Dollars as of June 4, 2020. F4 · derivative.exercise_date: These share options will vest in four equal annual installments beginning on June 4, 2021 and be automatically exercised upon vesting. F4 · derivative.expiration_date: These share options will vest in four equal annual installments beginning on June 4, 2021 and be automatically exercised upon vesting. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 20:06 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | GrantShare Options · Derivative | 149,856 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-015701 · doc4.xml · derivative · entry 1 Snyder Douglas B. · CIK 0001754125 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,856 Underlying: Ordinary Shares · 149,856 shares Expires not disclosed F1 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest and be automatically exercised on June 4, 2023 if certain performance conditions are satisfied. F3 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.26 U.S. Dollars as of June 4, 2020. F1 · derivative.exercise_date: Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest and be automatically exercised on June 4, 2023 if certain performance conditions are satisfied. F1 · derivative.expiration_date: Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest and be automatically exercised on June 4, 2023 if certain performance conditions are satisfied. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 18:03 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | SaleOrdinary Shares | 2,568 | $8.32 | $21,365.76 |
DisclosureSEC source: 0000899243-20-006998 · doc4.xml · nonDerivative · entry 1 Snyder Douglas B. · CIK 0001754125 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,296 F1 · kind: Automatic sale to cover vested restricted stock units that have been previously reported in Column 5 of Table I. F2 · shares: Represented by American Depositary Shares of the Issuer ("ADS"). Each ADS represents twelve ordinary shares of the Issuer. F3 · price: The price reported is price per ordinary share converted from price per ADS. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 18:06 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | SaleOrdinary Shares | 240 | $9.20 | $2,208.00 |
DisclosureSEC source: 0000899243-20-006331 · doc4.xml · nonDerivative · entry 2 Snyder Douglas B. · CIK 0001754125 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,864 F1 · kind: Automatic sale of vested restricted stock units that have been previously reported in Column 5 of Table I. F2 · shares: Represented by American Depositary Shares of the Issuer ("ADS"). Each ADS represents twelve ordinary shares of the Issuer. F3 · price: The price reported is price per ordinary share converted from price per ADS. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.